HitGen, Inc. Hits Day Low at CNY 33.44 Amid Price Pressure

HitGen, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, experienced a notable decline today, with its stock price dropping by 3.21%. The stock reached an intraday low of CNY 33.44, reflecting a challenging trading session. Despite this day's downturn, HitGen has shown strong performance metrics over the past year, boasting a remarkable 47.13% increase, significantly outperforming the China Shanghai Composite, which only gained 1.14% during the same period. The company's year-to-date performance stands at 44.18%, further highlighting its resilience in a fluctuating market. Financially, HitGen reported a substantial net profit growth of 114.98% as of September 25, alongside an impressive operating cash flow of CNY 204.8 million. The return on capital employed (ROCE) reached a high of 8.01%, and the pre-tax profit for the quarter was CNY 43.75 million, marking a growth of 150.73%. With a market capitalization of CNY 15,382 million and a P/E ratio of 87.00, HitGen continues to maintain a solid position within its industry, despite today's stock performance.